New treatment option for the acute phase of the rare disease TTP

Thrombotic Thrombocytopenic Purpura (TTP) is a rare disorder caused by an enzyme deficiency. This can be heriditary or can be acquired as an autoimmune condition. Due to the associated excessive activity of a certain protein, blood clots enriched with blood platelets form and block the smallest blood vessels. The disorder is life-threatening and very difficult to treat, particularly in the acute phase. Researchers have developed a treatment strategy to prevent this clotting in the blood vessels.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1QY8fXf